Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective Study.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 06 2022
Historique:
received: 11 05 2021
revised: 12 01 2022
accepted: 26 01 2022
pubmed: 7 2 2022
medline: 18 5 2022
entrez: 6 2 2022
Statut: ppublish

Résumé

Tumor and target volume manual delineation remains a challenging task in head and neck cancer radiation therapy. The purpose of this study was to conduct a multi-institutional evaluation of manual delineations of gross tumor volume (GTV), high-risk clinical target volume (CTV), parotids, and submandibular glands on treatment simulation magnetic resonance scans of patients with oropharyngeal cancer. We retrospectively collected pretreatment T1-weighted, T1-weighted with gadolinium contrast, and T2-weighted magnetic resonance imaging scans for 4 patients with oropharyngeal cancer under an institution review board-approved protocol. We provided the scans to 26 radiation oncologists from 7 international cancer centers that participated in this delineation study. We also provide the patients' clinical history and physical examination findings, along with a medical photographic image and radiologic results. We used both the Simultaneous Truth and Performance Level Estimation algorithm and pair-wise comparisons of the contours, using overlap/distance metrics. Lastly, to assess experience and CTV delineation institutional practices, we had participants complete a brief questionnaire. Large variability was measured between observers' delineations for GTVs and CTVs. The mean Dice similarity coefficient values across all physicians' delineations for GTVp, GTVn, CTVp, and CTVn were 0.77, 0.67, 0.77, and 0.69, respectively, for Simultaneous Truth and Performance Level Estimation algorithm comparison, and 0.67, 0.60, 0.67, and 0.58, respectively, for pair-wise analysis. Normal tissue contours were defined more consistently when considering overlap/distance metrics. The median radiation oncology clinical experience was 7 years. The median experience delineating on magnetic resonance imaging was 3.5 years. The GTV-to-CTV margin used was 10 mm for 6 of 7 participant institutions. One institution used 8 mm, and 3 participants (from 3 different institutions) used a margin of 5 mm. The data from this study suggests that appropriate guidelines, contouring quality assurance sessions, and training are still needed for the adoption of magnetic resonance-based treatment planning for head and neck cancers. Such efforts should play a critical role in reducing delineation variation and ensure standardization of target design across clinical practices.

Identifiants

pubmed: 35124134
pii: S0360-3016(22)00096-7
doi: 10.1016/j.ijrobp.2022.01.050
pmc: PMC9119288
mid: NIHMS1801452
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

426-436

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIDCR NIH HHS
ID : F31 DE029093
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214825
Pays : United States
Organisme : NIBIB NIH HHS
ID : R25 EB025787
Pays : United States
Organisme : NIDCR NIH HHS
ID : R56 DE025248
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218148
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097007
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257814
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028290
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Phys Med Biol. 2017 Nov 14;62(23):9140-9158
pubmed: 29049027
Clin Transl Radiat Oncol. 2018 Aug 02;12:40-46
pubmed: 30148217
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):220-7
pubmed: 22035663
Head Neck. 2004 Mar;26(3):241-6
pubmed: 14999799
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):468-478
pubmed: 29559291
Radiother Oncol. 2018 Jan;126(1):25-36
pubmed: 29153464
Radiol Oncol. 2016 May 09;50(3):254-62
pubmed: 27679540
Cancer. 2014 Mar 1;120(5):702-10
pubmed: 24421077
Radiother Oncol. 2019 Aug;137:9-15
pubmed: 31048235
Radiother Oncol. 2020 Dec;153:15-25
pubmed: 33039428
Front Oncol. 2020 Sep 07;10:1328
pubmed: 33014774
Jacobs J Radiat Oncol. 2014 Sep;1(1):006
pubmed: 25568889
Semin Radiat Oncol. 2004 Jan;14(1):52-64
pubmed: 14752733
Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):726-32
pubmed: 16626888
Radiother Oncol. 2014 Jan;110(1):172-81
pubmed: 24183870
IEEE Trans Med Imaging. 2004 Jul;23(7):903-21
pubmed: 15250643
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8
pubmed: 19394158
Radiother Oncol. 2012 Sep;104(3):343-8
pubmed: 22853852
Comput Med Imaging Graph. 2021 Jun;90:101907
pubmed: 33845433
Radiat Oncol. 2010 Mar 15;5:21
pubmed: 20230613
Radiother Oncol. 2018 Jan;126(1):43-47
pubmed: 28987748
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1606-1618
pubmed: 33340604
Phys Imaging Radiat Oncol. 2020 Apr 29;14:1-5
pubmed: 33458306
Biomed Imaging Interv J. 2006 Jan;2(1):e19
pubmed: 21614217
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Phys Med Biol. 2015 Nov 21;60(22):R323-61
pubmed: 26509844
Front Oncol. 2017 Apr 03;7:59
pubmed: 28421162
Clin Transl Radiat Oncol. 2018 Aug 24;13:19-23
pubmed: 30386824
Acta Oncol. 2016 Nov;55(11):1305-1312
pubmed: 27607138
Radiother Oncol. 2006 Apr;79(1):15-20
pubmed: 16616387
Radiother Oncol. 2012 Apr;103(1):92-8
pubmed: 22405806
Semin Radiat Oncol. 2014 Jul;24(3):196-9
pubmed: 24931092
Radiother Oncol. 2018 Jan;126(1):3-24
pubmed: 29180076
J Med Imaging Radiat Sci. 2017 Jun;48(2):184-192
pubmed: 31047367
Radiother Oncol. 2017 Apr;123(1):63-70
pubmed: 28259450
Int J Radiat Oncol Biol Phys. 2017 Jul 1;98(3):532-540
pubmed: 28258898
Phys Med Biol. 2009 Jun 21;54(12):N229-37
pubmed: 19451689
Radiother Oncol. 2003 Dec;69(3):227-36
pubmed: 14644481
Eur J Nucl Med. 1998 Sep;25(9):1255-60
pubmed: 9724374
Phys Med Biol. 2018 Nov 07;63(21):215026
pubmed: 30403188
Pract Radiat Oncol. 2014 Sep-Oct;4(5):279-284
pubmed: 25194094
Phys Med Biol. 2017 Aug 21;62(18):7233-7248
pubmed: 28749375
Radiother Oncol. 2008 Jan;86(1):25-9
pubmed: 18023488
BMC Cancer. 2015 Nov 04;15:844
pubmed: 26530182

Auteurs

Carlos E Cardenas (CE)

Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: cecardenas@uabmc.edu.

Sanne E Blinde (SE)

Department of Radiation Oncology, Klinikum Kassel, Kassel, Germany.

Abdallah S R Mohamed (ASR)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Sweet Ping Ng (SP)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Radiation Oncology, Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, Melbourne, Australia.

Cornelis Raaijmakers (C)

Department of Radiation Therapy, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Marielle Philippens (M)

Department of Radiation Therapy, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Alexis Kotte (A)

Department of Radiation Therapy, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Abrahim A Al-Mamgani (AA)

Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.

Irene Karam (I)

Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

David J Thomson (DJ)

Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, United Kingdom.

Jared Robbins (J)

Department of Radiation Oncology, University of Arizona, Tucson, Arizona.

Kate Newbold (K)

Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.

Clifton D Fuller (CD)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Chris Terhaard (C)

Department of Radiation Therapy, Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH